Aarti Drugs Q1 FY27 Earnings Call Transcript Released
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore, up 19% YoY. EBITDA grew 30% to ₹96.9 crore with a 13.8% margin. Standalone revenue increased 20% to ₹627.6 crore. The company is expanding its Sayakha and Baddi facilities and targeting 10-15% volume growth over the next two years.
The release of an earnings call transcript provides detailed insights into the company's performance and future strategy, which is material information for investors. The reported financial growth and expansion plans indicate a positive outlook.
The company reported strong year-on-year growth in revenue and EBITDA, with improved margins. Management expressed confidence in future growth prospects due to capacity expansions and strategic initiatives.
Aarti Drugs Limited has released the transcript for its Q1 FY27 Earnings Conference Call, which took place on August 3, 2026. The call featured management including Mr. Adhish Patil (COO & CFO), Mr. Harshit Savla (Joint Managing Director), and Mr. Harit Shah (Whole-Time Director).
The management discussed the operating environment, noting the influence of geopolitical developments like the conflict in West Asia, which led to elevated freight costs and volatile raw material pricing. However, this also created a favorable pricing environment for several API products, resulting in better realizations for the company. They emphasized their operational resilience, with no production disruptions experienced during the quarter.
Financially, consolidated revenue for Q1 FY27 stood at ₹703.6 crore, a 19% year-on-year growth from ₹590.8 crore in Q1 FY26. EBITDA grew by 30% to ₹96.9 crore, with an EBITDA margin of 13.8%, an expansion of 120 basis points. PBT grew 35% year-on-year to ₹69.2 crore, with a PBT margin of 9.9%. PAT was ₹50.1 crore, compared to ₹54.0 crore in Q1 FY26 (which included a ₹15 crore tax refund).
Standalone revenue for Q1 FY27 was ₹627.6 crore, a 20% year-on-year growth. The API business saw contributions from antibiotic (35.0%), antiprotozoal (18.5%), anti-inflammatory (11.9%), and antidiabetic (18.2%) categories, among others. The formulations business revenue grew 8% to ₹81.6 crore, with exports contributing 74%.
Discussions also covered the expansion of the Sayakha facility, planned ramp-up of the Baddi facility to double oral solid dosage capacity, and the strategic focus on backward integration and regulated markets, including USFDA approvals for Metformin. The company aims for 10-15% volume growth in the next two years.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.